Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes

Authors Lee C, Choi JS, Kim I, Oh KT, Lee ES, Park E, Lee KC, Youn YS

Received 13 May 2013

Accepted for publication 10 June 2013

Published 9 August 2013 Volume 2013:8(1) Pages 2975—2983


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Changkyu Lee,1 Ji Su Choi,1 Insoo Kim,1 Kyung Taek Oh,2 Eun Seong Lee,3 Eun-Seok Park,1 Kang Choon Lee,1 Yu Seok Youn1

1School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; 2College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea; 3Division of Biotechnology, The Catholic University of Korea, Bucheon-si, Republic of Korea

Abstract: Inhalable glycol chitosan-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing palmitic acid-modified exendin-4 (Pal-Ex4) (chitosan Pal-Ex4 PLGA NPs) were prepared and characterized. The surface morphology, particle size, and zeta potential of chitosan Pal-Ex4 PLGA NPs were investigated, and the adsorption and cytotoxicity of chitosan Pal-Ex4 PLGA NPs were evaluated in human lung epithelial cells (A549). Finally, the lung deposition characteristics and hypoglycemia caused by chitosan Pal-Ex4 PLGA NPs were evaluated after pulmonary administration in imprinting control region (ICR) and type 2 diabetic db/db mice. Results showed that chitosan Pal-Ex4 PLGA NPs were spherical, compact and had a diameter of ~700 nm and a positive surface charge of +28.5 mV. Chitosan-coated PLGA NPs were adsorbed onto A549 cells much more so than non-coated PLGA NPs. Pal-Ex4 release from chitosan-coated PLGA NPs was delayed by as much as 1.5 days as compared with chitosan-coated Ex4 PLGA NPs. In addition, chitosan-coated PLGA NPs remained in the lungs for ~72 hours after pulmonary administration, whereas most non-coated PLGA NPs were lost at 8 hours after administration. Furthermore, the hypoglycemic efficacy of inhaled chitosan Pal-Ex4 PLGA NPs was 3.1-fold greater than that of chitosan Ex4 PLGA NPs in db/db mice. The authors believe chitosan Pal-Ex4 PLGA NPs have considerable potential as a long-acting inhalation delivery system for the treatment of type 2 diabetes.

Keywords: chitosan-coating, PLGA nanoparticles, inhalation, exendin-4, type 2 diabetes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]